Product Description
Mechanisms of Action: FGFR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Kaken Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Diabetic Foot|Periodontitis|Alveolar Bone Loss|Periodontal Attachment Loss
Phase 2: Periodontitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| The TRAfermin in Neuropathic diabetic foot ulcer Study - southern Europe. The TRANS-North study | P3 |
Completed |
Diabetic Foot |
2013-02-06 |
|
| The TRAfermin in Neuropathic diabetic foot ulcer Study - northern Europe. The TRANS-North study | P3 |
Terminated |
Diabetic Foot |
2012-09-30 |
|
| TRANS-North | P3 |
Completed |
Diabetic Foot |
2012-05-01 |
|
| TRANS-South | P3 |
Completed |
Diabetic Foot |
2012-03-01 |